Compounds > 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone

3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone and Dry-Eye-Syndromes

3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone has been researched along with Dry-Eye-Syndromes* in 1 studies

Other Studies

1 other study(ies) available for 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone and Dry-Eye-Syndromes

ArticleYear
Nanomolar Potency Aminophenyltriazine CFTR Activator Reverses Corneal Epithelial Injury in a Mouse Model of Dry Eye.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2020, Volume: 36, Issue:3

    Topics: Administration, Topical; Animals; Benzoates; Cautery; Chloride Channels; Corneal Injuries; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Dry Eye Syndromes; Female; Lacrimal Apparatus; Lissamine Green Dyes; Mice; Mice, Inbred BALB C; Nanotechnology; Tears; Thiazolidines; Treatment Outcome; Triazines

2020